Vitrakvi Larotrectinib NTRK Fusion Tumor Agnostic Review 2026
Author: Critical Kare PharmaGenomic Oncology Desk
On October 30, 2026, precision oncology societies highlighted Vitrakvi® (Larotrectinib 100 mg and 25 mg capsules, 20 mg/mL oral solution) by Bayer as the paradigm-defining first-in-class tumor-agnostic TRK inhibitor.
Vitrakvi provides durable disease control across all solid tumors harboring neurotrophic receptor tyrosine kinase (NTRK1, NTRK2, NTRK3) gene fusions in pediatric and adult patients, regardless of cancer tissue origin.
Through Critical Kare Pharma, original manufacturer supplies of Vitrakvi Larotrectinib Capsules and Oral Solution are supplied globally with complete Certificate of Analysis documentation.
Mechanism of Action & Clinical Efficacy
- Highly Selective TRK Inhibition: Nanomolar inhibition of TRKA, TRKB, and TRKC catalytic domains, halting constitutively active chimeric TRK oncoproteins.
- Durable Objective Responses: Sustained overall response rates of 75% across more than 25 distinct tumor histologies, including infantile fibrosarcoma, salivary gland cancer, thyroid cancer, and lung adenocarcinoma.
- Dosing: 100 mg orally twice daily in adults; 100 mg/m² twice daily in pediatric patients (max 100 mg per dose).
Global Access via Critical Kare Pharma
Imported under named-patient schemes worldwide with express temperature-controlled transit within 4–8 business days.
